CLINICAL TRIALS PROFILE FOR BYQLOVI

All Clinical Trials for BYQLOVI

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT07276802 ↗	The TRIBECA Study (TRIessence/Byqlovi for Easier CAtaract Surgery)	NOT_YET_RECRUITING	Research Insight LLC	PHASE4	2025-12-05	A self-controlled, prospective clinical study of the safety, clinical efficacy, and patient acceptance of subconjunctival delivery of triamcinolone 40 mg/mL (Triesence) at the conclusion of cataract surgery or topical clobetasol 0.05 (Byqlovi) BID for 14 days, with intracameral moxifloxacin 0.5%, and topical nepafenac 0.3% (Ilevro) for 14 days, as compared to traditional topical postoperative prednisolone acetate 1% QID, moxifloxacin 0.5% drops QID, and ketorolac 0.5% QID in controlling postoperative pain and inflammation in subjects undergoing sequential bilateral cataract surgery.

Clinical Trial Conditions for BYQLOVI

Condition Name

Condition Name for BYQLOVI
Intervention	Trials
Post Cataract Surgery	1

Condition MeSH

Condition MeSH for BYQLOVI
Intervention	Trials

Clinical Trial Locations for BYQLOVI

Trials by Country

Trials by Country for BYQLOVI
Location	Trials
United States	1

Trials by US State

Trials by US State for BYQLOVI
Location	Trials
California	1

Clinical Trial Progress for BYQLOVI

Clinical Trial Phase

Clinical Trial Phase for BYQLOVI
Clinical Trial Phase	Trials
PHASE4	1

Clinical Trial Status

Clinical Trial Status for BYQLOVI
Clinical Trial Phase	Trials
NOT_YET_RECRUITING	1

Clinical Trial Sponsors for BYQLOVI

Sponsor Name

Sponsor Name for BYQLOVI
Sponsor	Trials
Research Insight LLC	1

Sponsor Type

Sponsor Type for BYQLOVI
Sponsor	Trials
INDUSTRY	1